Original ResearchFull Report: Clinical—Alimentary TractEfficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
Graphical abstract
Keywords
Abbreviations used in this paper
Cited by (0)
Conflicts of interestThe authors disclose the following: William J. Sandborn: Financial support for research: Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, AbbVie, Janssen, Takeda, Lilly, Celgene/Receptos, Pfizer, Prometheus Laboratories; Consulting fees: Abbvie, Allergan, Amgen, Arena Pharmaceuticals, Avexegen Therapeutics, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pfizer, Precision IBD, Progenity, Prometheus Laboratories, Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust, HART), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB Pharma, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals; Stock or stock options: BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan Pharma, Precision IBD, Progenity, Ritter Pharmaceuticals, Ventyx Biosciences, Vimalan Biosciences. Spouse: Opthotech–consultant, stock options; Progenity–consultant, stock; Oppilan Pharma–employee, stock options; Escalier Biosciences–employee, stock options; Precision IBD–employee, stock options; Ventyx Biosciences–employee, stock options; Vimalan Biosciences–employee, stock options. Filip Baert: Financial support for research: AbbVie, Chiesi, Ipsen, MSD, Roche; Consultancy: AbbVie, Celgene, Falk, Ferring, Janssen, Mundipharma, MSD, Pfizer, Takeda, Vifor. Silvio Danese: Lecture fees: AbbVie, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim; Consultancy: AbbVie, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim. Željko Krznarić: Lecture fees: AbbVie, Hospira, Johnson & Johnson, MSD, Oktal Pharma. Taku Kobayashi: Financial support for research: EA Pharma, Thermo Fisher Scientific, Alfresa Pharma, and Nippon Kayaku. Lecture fees: Mitsubishi Tanabe Pharma, Pfizer, Eisai, Kyorin Pharmaceutical, AbbVie, Janssen, JIMRO, Ajinomoto Pharma, EA Pharma, Astellas Pharma, Mochida Pharmaceutical, Asahi Kasei Medical, Takeda, Gilead Sciences, Celltrion, Nippon Kayaku, Alfresa Pharma; Consultancy: Janssen, Pfizer, Kyorin Pharmaceutical, Mochida Pharmaceutical, Takeda, Eli Lilly, Ferring Pharmaceutical, Nippon Kayaku, Thermo Fisher Scientific, Covidien Japan. Xiaopan Yao: Employee of Takeda at the time the study was conducted. Jingjing Chen: Employee of Takeda. Maria Rosario: Employee of Takeda. Siddharth Bhatia: Employee of Takeda. Krisztina Kisfalvi: Employee of Takeda. Geert D’Haens: Lecture fees: AbbVie, Biogen, Ferring, Johnson & Johnson, Merck Sharp Dohme, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millennium/Takeda, Tillotts and Vifor; Consultancy: AbbVie, Ablynx, Allergan, Amakem, Amgen, AM Pharma, Arena Pharmaceuticals, AstraZeneca, Avaxia, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene/Receptos, Celltrion, Cosmo, Covidien/Medtronics, Echo Pharmaceuticals, Eli Lilly, Engene, Ferring, DrFALK Pharma, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Gossamerbio, Hospira/Pfizer, Immunic, Johnson & Johnson, Lycera, Medimetrics, Millennium/Takeda, Mitsubishi Pharma, Merck Sharp Dohme, Mundipharma, Nextbiotics, Novo Nordisk, Otsuka, Pfizer/Hospira, Photopill, Prometheus Laboratories/Nestle, Progenity, Protagonist, Robarts Clinical Trials, Salix, Samsung Bioepis, Sandoz, Seres/Nestle, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor. Séverine Vermeire: Financial support for research: MSD, AbbVie, Takeda, Pfizer, Johnson & Johnson; Lecture fees: MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech/Roche; Consultancy: MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech/Roche, Celgene, Mundipharma, Celltrion, SecondGenome, Prometheus, Gilead, Galapagos, ProDigest.
FundingThis study was sponsored by Takeda. Personnel from the study sponsor designed the trial in conjunction with the principal investigators. Takeda analyzed the data, and with all authors jointly interpreted the results.
Author names in bold designate shared co-first authorship.